Fri, Aug 22, 2014, 1:57 PM EDT - U.S. Markets close in 2 hrs 3 mins

Recent

% | $
Quotes you view appear here for quick access.

Astex Pharmaceuticals, Inc. Message Board

  • michaelplongo michaelplongo May 24, 2013 3:37 PM Flag

    Abstract Submission EHA18ABSSUB-3339 OUTCOMES OF INTERMEDIATE OR HIGH RISK MYELODYSPLASTIC SYNDROMES (MDS) PATIENTS POST AZACITIDINE AND/OR DECITABINE TREATMENT FAILURES WITH SGI-110, A NOVEL SECOND GENERATION HYPOMETHYLATING AGENT (HMA)

    Results: Fifteen patients with Intermediate-1 (3), Intermediate-2 (5), High Risk (6) MDS and 1 with CMML, … were enrolled. All patients enrolled (100%) had prior treatment with decitabine and/or azacitidine; 87% had prior azacitidine, 53% had prior decitabine, and 40% had both azacitidine and decitabine as prior treatment2Responses were observed in 5 patients for an overall response rate of 33% with reported response duration of 28–224 days. Details of each of the 5 responders are shown in Table 1. The median bone marrow blast count at baseline for the responders was 16.5% while the non-responders were 5%. Median LINE1 demethylation in responders showed a decrease by -19.3% compared to -12.0% in non-responders.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
ASTX
8.4950.000(0.00%)Oct 10 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.